S Keisin Wang1, Linden A Green1, Natalie A Drucker1, Raghu L Motaganahalli1, Andres Fajardo1, Michael P Murphy2. 1. Division of Vascular Surgery, Department of Surgery, Indiana University School of Medicine, Richard L. Roudebush VA Medical Center, and VA Center for Molecular and Cellular Therapeutics in Cardiovascular Disease, Indianapolis, Ind. 2. Division of Vascular Surgery, Department of Surgery, Indiana University School of Medicine, Richard L. Roudebush VA Medical Center, and VA Center for Molecular and Cellular Therapeutics in Cardiovascular Disease, Indianapolis, Ind. Electronic address: mipmurph@iupui.edu.
Abstract
OBJECTIVE: Currently, there are no accepted nonsurgical therapies that improve the delivery of blood-derived nutrients to patients with critical limb ischemia. Here, we describe the ongoing phase 1/2 Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial, which will provide crucial evidence of the safety profile of mesenchymal stromal cells (MSCs) and explore their therapeutic mechanisms in the setting of critical limb ischemia requiring below-knee amputation (BKA). METHODS: In the CHAMP and the parallel marrowCHAMP trials (hereafter grouped together as CHAMP), a total of 32 extremities with rest pain or tissue loss requiring BKA will be enrolled to receive intramuscular injections of allogeneic MSCs (CHAMP; n = 16) or autogenous concentrated bone marrow aspirate (marrowCHAMP; n = 16) along the distribution of the BKA myocutaneous flap and proximal tibialis anterior. After treatment, subjects are randomized to BKA at four time points after injection (days 3, 7, 14, and 21). At the time of amputation, skeletal muscle is collected at 2-cm increments from the tibialis injection site and used to determine proangiogenic cytokine description, MSC retention, quantification of proangiogenic hematopoietic progenitor cells, and histologic description. Clinical limb perfusion before and after treatment will be quantified using transcutaneous oximetry, toe-brachial index, ankle-brachial index, and indocyanine angiography. Additional clinical end points include all-cause mortality, need for amputation revision, and gangrene incidence during the 6-month post-treatment follow-up. RESULTS: Enrollment is under way, with 10 patients treated per protocol thus far. We anticipate full conclusion of follow-up within the next 24 months. CONCLUSIONS:CHAMP will be pivotal in characterizing the safety, efficacy, and, most important, therapeutic mechanism of allogeneic MSCs and autogenous concentrated bone marrow aspirate in ischemic skeletal muscle.
RCT Entities:
OBJECTIVE: Currently, there are no accepted nonsurgical therapies that improve the delivery of blood-derived nutrients to patients with critical limb ischemia. Here, we describe the ongoing phase 1/2 Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial, which will provide crucial evidence of the safety profile of mesenchymal stromal cells (MSCs) and explore their therapeutic mechanisms in the setting of critical limb ischemia requiring below-knee amputation (BKA). METHODS: In the CHAMP and the parallel marrowCHAMP trials (hereafter grouped together as CHAMP), a total of 32 extremities with rest pain or tissue loss requiring BKA will be enrolled to receive intramuscular injections of allogeneic MSCs (CHAMP; n = 16) or autogenous concentrated bone marrow aspirate (marrowCHAMP; n = 16) along the distribution of the BKAmyocutaneous flap and proximal tibialis anterior. After treatment, subjects are randomized to BKA at four time points after injection (days 3, 7, 14, and 21). At the time of amputation, skeletal muscle is collected at 2-cm increments from the tibialis injection site and used to determine proangiogenic cytokine description, MSC retention, quantification of proangiogenic hematopoietic progenitor cells, and histologic description. Clinical limb perfusion before and after treatment will be quantified using transcutaneous oximetry, toe-brachial index, ankle-brachial index, and indocyanine angiography. Additional clinical end points include all-cause mortality, need for amputation revision, and gangrene incidence during the 6-month post-treatment follow-up. RESULTS: Enrollment is under way, with 10 patients treated per protocol thus far. We anticipate full conclusion of follow-up within the next 24 months. CONCLUSIONS:CHAMP will be pivotal in characterizing the safety, efficacy, and, most important, therapeutic mechanism of allogeneic MSCs and autogenous concentrated bone marrow aspirate in ischemic skeletal muscle.
Authors: M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz Journal: Cytotherapy Date: 2006 Impact factor: 5.414
Authors: Scott Maxson; Erasmo A Lopez; Dana Yoo; Alla Danilkovitch-Miagkova; Michelle A Leroux Journal: Stem Cells Transl Med Date: 2012-02 Impact factor: 6.940
Authors: S Keisin Wang; Linden A Green; Raghu L Motaganahalli; Michael G Wilson; Andres Fajardo; Michael P Murphy Journal: J Vasc Surg Date: 2017-04-05 Impact factor: 4.268
Authors: Mark R Nehler; Joseph R Coll; William R Hiatt; Judith G Regensteiner; Gabriel T Schnickel; William A Klenke; Pam K Strecker; Michelle W Anderson; Darrell N Jones; Thomas A Whitehill; Shevie Moskowitz; William C Krupski Journal: J Vasc Surg Date: 2003-07 Impact factor: 4.268
Authors: Kristina A Giles; Eva M Rzucidlo; Philip P Goodney; Daniel B Walsh; Richard J Powell Journal: J Vasc Surg Date: 2014-07-30 Impact factor: 4.268
Authors: Tiffany W Liang; Andrea Jester; Raghu L Motaganahalli; Michael G Wilson; Patricia G'Sell; George A Akingba; Andres Fajardo; Michael P Murphy Journal: J Vasc Surg Date: 2016-03-23 Impact factor: 4.268
Authors: Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén Journal: Lancet Date: 2008-05-10 Impact factor: 79.321
Authors: Christopher Heeschen; Ralf Lehmann; Jörg Honold; Birgit Assmus; Alexandra Aicher; Dirk H Walter; Hans Martin; Andreas M Zeiher; Stefanie Dimmeler Journal: Circulation Date: 2004-03-22 Impact factor: 29.690
Authors: Michael P Murphy; Hao Wang; Amit N Patel; Suman Kambhampati; Niren Angle; Kyle Chan; Annette M Marleau; Andrew Pyszniak; Ewa Carrier; Thomas E Ichim; Neil H Riordan Journal: J Transl Med Date: 2008-08-19 Impact factor: 5.531
Authors: S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai Journal: Cochrane Database Syst Rev Date: 2018-08-29
Authors: Laura V Lozano Navarro; Xueyi Chen; Lady Tatiana Giratá Viviescas; Andrea K Ardila-Roa; Maria L Luna-Gonzalez; Claudia L Sossa; Martha L Arango-Rodríguez Journal: Stem Cell Res Ther Date: 2022-07-26 Impact factor: 8.079
Authors: Rhayra B Dias; João A M Guimarães; Marco B Cury; Leonardo R Rocha; Elaine S da Costa; Liebert P Nogueira; Camila Hochman-Mendez; Anneliese Fortuna-Costa; Anna Karoline F Silva; Karin S Cunha; Sergio A L de Souza; Maria Eugênia L Duarte; Rafaela C Sartore; Danielle C Bonfim Journal: Stem Cells Int Date: 2019-11-07 Impact factor: 5.443